Author:
Perry Robert T.,Murray Jillian S.,Gacic-Dobo Marta,Dabbagh Alya,Mulders Mick N.,Strebel Peter M.,Okwo-Bele Jean-Marie,Rota Paul A.,Goodson James L.
Publisher
Centers for Disease Control MMWR Office
Subject
Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health(social science),Epidemiology
Reference9 articles.
1. World Health Organization. Global eradication of measles: report by the Secretariat. Geneva, Switzerland: World Health Organization; 2010. Available at http://apps.who.int/gb/ebwha/pdf_files/wha63/a63_18-en.pdf.
2. Progress toward regional measles elimination—worldwide, 2000–2013.;Perry;MMWR Morb Mortal Wkly Rep,2014
3. Genetic diversity of wild-type measles viruses and the global measles nucleotide surveillance database (MeaNS).;World Health Organization;Wkly Epidemiol Rec,2015
4. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data.;Simons;Lancet,2012
5. Tracking measles infection through non-linear state space models.;Chen;J R Stat Soc Ser C Appl Stat,2012
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The Reasoning through Evidence versus Advice (EvA) Scale: Scale Development and Validation;Journal of Personality Assessment;2024-01-25
2. Preferences for Sexually Transmitted Infection and Cancer Vaccines in the United States and in China;Value in Health;2023-02
3. Viral Infections;Dermatology in Public Health Environments;2023
4. Second-dose measles vaccination and associated factors among under-five children in urban areas of North Shoa Zone, Central Ethiopia, 2022;Frontiers in Public Health;2022-12-09
5. Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial];Trials;2022-09-14